Abstract

BackgroundThe optimal revascularization strategy for patients with impaired glomerular filtration rate (IGFR) has not been established in acute coronary syndrome (ACS). We investigated the prognosis and impact of IGFR and invasive strategy on the cardiovascular outcomes in the ACS population.MethodsIn a Taiwan national-wide registry, 3093 ACS patients were enrolled. The invasive strategy was defined as patients with ST-elevation ACS (STE-ACS) undergoing primary angioplasty or fibrinolysis or coronary angiography with intent to revascularization performed within 72 hours of symptom onset in non-ST-elevation ACS (NSTE-ACS). IGFR was defined as an estimated GFR of less than 60 ml/min per 1.73 m2. Primary endpoint was a composite of death, non-fatal myocardial infarction or stroke at one year.ResultsPatients with IGFR (n = 1226) had more comorbidities but received less evidence-based medications during admission than those without IGFR (n = 1867). The primary endpoint-free survival rate is lower in the IGFR patients, in the whole, STE-ACS and NSTE-ACS population (all log-rank tests p < 0.01). Cox regression analysis revealed IGFR subjects had higher primary endpoint after adjusting by age, sex, medication at discharge and traditional risk factors (all p < 0.01). Kaplan–Meier curves showed IGFR patients without invasive strategy had the worst outcome in the STE-ACS and NSTE-ACS population (both p < 0.01). The invasive strategies, either with early angiography only or angioplasty, were associated with reduced primary endpoints among IGFR patients in the NSTE-ACS population (both p ≦ 0.024).ConclusionsIGFR patients suffering from ACS had poor prognosis and an invasive strategy could improve cardiovascular outcome in the NSTE-ACS population.

Highlights

  • The optimal revascularization strategy for patients with impaired glomerular filtration rate (IGFR) has not been established in acute coronary syndrome (ACS)

  • 3093 (97.1%) subjects with renal parameters and 12 months outcome data were analyzed in this study and 1631 (52.7%) patients were ST-elevation ACS (STE-ACS)

  • Cox regression analysis found the adjusted hazard ratio (HR) of presence of IGFR in the whole, STE-ACS and NSTE-ACS populations were 1.98 (95% confidence interval (CI): 1.44-2.73), 1.78 (CI: 1.17-2.72) and 2.27 (CI: 1.38-3.74) for the primary endpoint, respectively

Read more

Summary

Introduction

The optimal revascularization strategy for patients with impaired glomerular filtration rate (IGFR) has not been established in acute coronary syndrome (ACS). We investigated the prognosis and impact of IGFR and invasive strategy on the cardiovascular outcomes in the ACS population. Patients with CKD have higher risk of progression to end-stage renal disease (ESRD) and poor cardiovascular prognosis [2]. Taiwan has been recognized as an epidemic area of kidney disease with the highest incidence and prevalence rates of ESRD in the world [3]. The development of effective treatment strategies is mandatory for such a high cardiovascular risk population. Recent major clinical trials have shown aggressive medication treatment can improve cardiovascular outcome in patients suffering from ACS, only few patients with impaired glomerular filtration rate (IGFR) were enrolled

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.